Breaking News Instant updates and real-time market news.

ALXN

Alexion

$120.24

-1.1 (-0.91%)

16:35
10/19/16
10/19
16:35
10/19/16
16:35

Alexion's ALXN1007 granted orphan drug designation from FDA

Alexion Pharmaceuticals announced that the U.S. Food and Drug Administration has granted orphan drug designation to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for the treatment of acute graft-versus-host disease. Alexion is currently investigating ALXN1007 in patients with acute GVHD of the lower gastrointestinal tract, a severe and life-threatening rare autoimmune disease that can occur as a complication of stem cell or bone marrow transplantation. "There is an urgent need for an effective treatment for GI-GVHD, which causes severe symptoms and often leads to mortality following allogeneic hematopoietic stem cell transplantation. Currently, even with best available care, about one-third of severely affected patients die from this devastating complication within six months of onset," said Martin Mackay, Ph.D., Executive Vice President and Global Head of R&D at Alexion. "Alexion is pleased that the FDA has granted orphan drug designation to ALXN1007, recognizing its potential to improve response rates in patients facing acute GI-GVHD." ALXN1007 is currently being evaluated in a Phase 2 study in patients with newly diagnosed acute GI-GVHD.

  • 27

    Oct

  • 02

    Nov

  • 06

    Nov

  • 11

    Nov

  • 14

    Dec

ALXN Alexion
$120.24

-1.1 (-0.91%)

10/04/16
BMUR
10/04/16
INITIATION
Target $221
BMUR
Buy
Alexion assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Alexion Pharmaceuticals with a Buy rating and $221 price target.
09/26/16
LEER
09/26/16
NO CHANGE
Target $211
LEER
Outperform
Alexion to dominate terminal complement inhibitor market, says Leerink
Leerink analyst Geoffrey Porges expects Alexion's flagship complement inhibition franchise to remain the dominant, if not only, terminal complement inhibitor on the market. The analyst notes that his research finds that the number of manufacturers with competing programs in early stage development face "significant" technical and market-related challenges to match or surpass Soliris. Porges continues to view Alexion's complement franchise as durable and capable of sustaining revenue growth throughout the mid-term as the company expands into other rare diseases. He reiterates an Outperform rating on the stock and raised his price target on the shares to $211 from $210.
09/23/16
JEFF
09/23/16
NO CHANGE
Target $120
JEFF
Hold
Alexion price target lowered to $120 from $140 at Jefferies
Jefferies analyst Eun Yang lowered her price target for Alexion Pharmaceuticals to $120 after conducting a survey of 35 U.S. hematologists/nephrologists. The survey results support a cautious outlook on Soliris sales in 2021 and beyond due to potential competition, Yang tells investors in a research note. Specifically, 60% of those surveyed will shift away from Soliris to biosimilars if they are available due to cost, Yang tells investors in a research note. The analyst keeps a Hold rating on Alexion.
09/23/16
WEDB
09/23/16
INITIATION
Target $132
WEDB
Neutral
Alexion initiated with a Neutral at Wedbush
Wedbush analyst Heather Behanna initiated Alexion with a Neutral and a $132 price target.

TODAY'S FREE FLY STORIES

JNPR

Juniper

$27.78

-0.49 (-1.73%)

16:35
04/25/17
04/25
16:35
04/25/17
16:35
Earnings
Juniper sees Q2 54c plus/minus 3c, consensus 53c »

Sees Q2 revenue $1.28B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    May

  • 08

    Jun

CHDN

Churchill Downs

$169.35

-0.35 (-0.21%)

16:34
04/25/17
04/25
16:34
04/25/17
16:34
Hot Stocks
Churchill Downs announces new $250M stock repurchase program »

The board of Churchill…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

TXN

Texas Instruments

$82.37

1.29 (1.59%)

16:34
04/25/17
04/25
16:34
04/25/17
16:34
Hot Stocks
Texas Instruments reports inventory at end of Q1 at 132 days »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 31

    May

EQR

Equity Residential

$64.93

0.73 (1.14%)

16:34
04/25/17
04/25
16:34
04/25/17
16:34
Earnings
Equity Residential sees Q2 normalized FFO 75c-79c »

Sees Q2 EPS 51c-55c, may…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 15

    Jun

JNPR

Juniper

$27.78

-0.49 (-1.73%)

16:33
04/25/17
04/25
16:33
04/25/17
16:33
Technical Analysis
Juniper nears 52-week high after results »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    May

  • 08

    Jun

EQR

Equity Residential

$64.93

0.73 (1.14%)

16:33
04/25/17
04/25
16:33
04/25/17
16:33
Earnings
Equity Residential reports Q1 normalized FFO 74c vs. 76c last year »

Reports Q1 EPS 39c,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 15

    Jun

TXN

Texas Instruments

$82.37

1.29 (1.59%)

16:33
04/25/17
04/25
16:33
04/25/17
16:33
Hot Stocks
Texas Instruments reports cash flow from operations $4.8B for trailing 12 months »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 31

    May

PEI

Pennsylvania REIT

$14.59

-0.01 (-0.07%)

16:33
04/25/17
04/25
16:33
04/25/17
16:33
Hot Stocks
Pennsylvania REIT reports Q1 same Store NOI was flat compared to prior year »

Reports Q1 same Store NOI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

OKSB

Southwest Bancorp

$25.75

0.2 (0.78%)

16:33
04/25/17
04/25
16:33
04/25/17
16:33
Earnings
Breaking Earnings news story on Southwest Bancorp »

Southwest Bancorp reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

PEI

Pennsylvania REIT

$14.59

-0.01 (-0.07%)

16:33
04/25/17
04/25
16:33
04/25/17
16:33
Earnings
Pennsylvania REIT reports Q1 EPS (10c), consensus (8c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CLGX

CoreLogic

$41.96

-0.14 (-0.33%)

16:32
04/25/17
04/25
16:32
04/25/17
16:32
Earnings
CoreLogic reports Q1 adjusted EPS 37c, consensus 39c »

Reports Q1 revenue $440M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

TXN

Texas Instruments

$82.37

1.29 (1.59%)

16:32
04/25/17
04/25
16:32
04/25/17
16:32
Hot Stocks
Breaking Hot Stocks news story on Texas Instruments »

Texas Instruments reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 31

    May

TXN

Texas Instruments

$82.37

1.29 (1.59%)

16:32
04/25/17
04/25
16:32
04/25/17
16:32
Earnings
Texas Instruments sees Q2 EPS 89c-$1.01, consensus 91c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 31

    May

JNS

Janus Capital

$13.45

0.02 (0.15%)

16:32
04/25/17
04/25
16:32
04/25/17
16:32
Hot Stocks
Janus Capital shareholders approve merger with Henderson Group »

Janus Capital Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

TRMK

Trustmark

$32.97

0.14 (0.43%)

16:31
04/25/17
04/25
16:31
04/25/17
16:31
Earnings
Trustmark reports Q1 EPS 46c, consensus 41c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

X

U.S. Steel

$31.11

-0.09 (-0.29%)

16:31
04/25/17
04/25
16:31
04/25/17
16:31
Hot Stocks
U.S. Steel drops over 15% in after-hours following earnings report »

U.S. Steel shares are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

16:31
04/25/17
04/25
16:31
04/25/17
16:31
Options
Preliminary option volume of 19.4M today »

Preliminary option volume…

TXN

Texas Instruments

$82.37

1.29 (1.59%)

16:30
04/25/17
04/25
16:30
04/25/17
16:30
Earnings
Texas Instruments reports Q1 EPS 97c, consensus 83c »

Reports Q1 revenue $3.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 31

    May

CHSP

Chesapeake Lodging

$24.70

0.29 (1.19%)

16:29
04/25/17
04/25
16:29
04/25/17
16:29
Earnings
Chesapeake Lodging sees Q2 AFFO 60c-64c »

Sees Q2 EPS 27c-30c,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 17

    May

TGI

Triumph Group

$26.20

-0.05 (-0.19%)

16:29
04/25/17
04/25
16:29
04/25/17
16:29
Hot Stocks
Triumph Group, VAS Aero collaborate on PW4168 Nacelles »

Triumph Group said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNPR

Juniper

$27.78

-0.49 (-1.73%)

16:28
04/25/17
04/25
16:28
04/25/17
16:28
Earnings
Juniper reports preliminary Q1 EPS 46c, consensus 42c »

Reports preliminary Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    May

  • 08

    Jun

CHSP

Chesapeake Lodging

$24.70

0.29 (1.19%)

16:28
04/25/17
04/25
16:28
04/25/17
16:28
Earnings
Chesapeake Lodging backs FY17 adjusted FFO $2.10-$2.20 »

Backs FY17 EPS 73c-83c,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 17

    May

ARCW

ARC Group

$3.85

0.05 (1.32%)

16:28
04/25/17
04/25
16:28
04/25/17
16:28
Hot Stocks
Breaking Hot Stocks news story on ARC Group »

Northern Right Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHSP

Chesapeake Lodging

$24.70

0.29 (1.19%)

16:27
04/25/17
04/25
16:27
04/25/17
16:27
Earnings
Chesapeake Lodging reports Q1 adjusted FFO 41c »

Reports Q1 EPS 9c,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 17

    May

BXMT

Blackstone Mortgage

$30.91

0.28 (0.91%)

16:26
04/25/17
04/25
16:26
04/25/17
16:26
Earnings
Blackstone Mortgage reports Q1 core EPS 61c, consensus 63c »

Reports book value of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.